Prestige Consumer Healthcare
PBH
#4715
Rank
$2.18 B
Marketcap
$46.19
Share price
1.92%
Change (1 day)
-23.00%
Change (1 year)

P/E ratio for Prestige Consumer Healthcare (PBH)

P/E ratio as of November 2026 (TTM): 14.1

According to Prestige Consumer Healthcare's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 14.1319. At the end of 2022 the company had a P/E ratio of 14.9.

P/E ratio history for Prestige Consumer Healthcare from 2005 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202214.9-7.6%
202116.153.12%
202010.5-115.61%
2019-67.5-368.86%
201825.1316.07%
20176.03-84.13%
201638.053.65%
201524.7-3.05%
201425.55.54%
201324.29.9%
201222.069.92%
201113.0-44.72%
201023.4-1188.1%
2009-2.15-114.29%
200815.130.97%
200711.5-43.43%
200620.3-117.9%
2005-114

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
42.9 203.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Procter & Gamble
PG
25.1 77.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
30.5 116.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
40.6 187.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
40.2 184.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Clorox
CLX
22.5 59.13%๐Ÿ‡บ๐Ÿ‡ธ USA
CVS Health
CVS
27.5 94.93%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
17.6 24.41%๐Ÿ‡ฌ๐Ÿ‡ง UK
Rite Aid
RAD
-0.0219-100.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Taro Pharmaceutical
TARO
70.4 398.47%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.